STUB1 and type 2 diabetes mellitus: Taken together, these findings suggest that integrating CHIP genotyping with lipidomic profiles and inflammatory biomarkers may refine T2D risk stratification and identify individuals who could benefit from targeted anti-inflammatory or metabolic interventions.